Member Info for Energyshares

Or is it Affyxell

It’s bugging me what CC said yesterday in the Panmure interview yesterday.

Re: Pathway inhibitors very effective in a number of diseases, but carry high toxicities. 15mins 35 secs not just chemo

She said

“We hope to see one of them come soon to the clinic”with a big smile.

I first thought TMac but Affyxell are using pathway inhibitors to block stem cells.

We are due news from Affyxell and CC & SB are on the board of Affyxell ……

https://www.ipgroupplc.com/news-and-events/portfolio-news/2020/2020-02-03

I think CC let slip in yesterday’s interview @15:35

pathway inhibitors that is TMAC AVA04

“We hope to see one of them come soon to the clinic”

https://drug-dev.com/avactas-proprietary-tmac-cancer-therapy-platform-demonstrates-successful-proof-of-concept/

https://avacta.com/wp-content/uploads/2019/10/POS022-PD-L1-in-Mouse-revision-1.pdf

https://avacta.com/wp-content/uploads/2023/04/AACR-2021_POS037.pdf

Thanks for link thevid.

Bit of a weird start CC goes from playing with dolls to playing with her phone and mouse.

But great end to interview lots now happening in background and with CC excitement on 6103 saying it’s what she has been waiting for in oncology all her life.

Wow feels like they have pushed the Big button last Friday to start letting the world know about the Pre/Cision platform.

GLA…,

So it looks like Avacta going for AA by smashing existing durable responses in an unmet medical need, SGC has no standard of care.

Durable Response:

A durable response, as evidenced by effects such as overall response rate and durability of the response, can be a factor in demonstrating clinical benefit and supporting accelerated approval.

https://pmc.ncbi.nlm.nih.gov/articles/PMC5604502/#:~:text=Traditional%20response%20criteria%20may%20be,benefit%20such%20as%20overall%20survival.

I’m still here all my research done just waiting for T/O for my exit.I still have all my holdings not sold a bean.

But spend less time on here because of the constant bore and his mates.

CBA interacting with them

GLA

Keep hold of them golden tickets..

Palex from Belgium,why didn’t they buy Coris aswell they are Belgium based lots of savings if they did.??????

The Company has seen a dramatic increase in therapeutic index in preclinical models, suggesting that AVA6103 could have an unprecedented safety profile in the clinic. AVA6103 has the potential to treat hundreds of thousands of patients with the broad use of the topo I drug class and over 90% of solid tumors expressing FAP.

Jan 16th last trial RNS update from Avacta.

Which was also the last day of the of the 2025 J.P. Morgan Healthcare Conference.

January 13-16, 2025

Has talks with a partner or suitor continued after the conference ?

🤞bring on the news get us all out of our misery.

GLA

A lot of moaning about finances and loan payments,trolls love to keep the negative stance going.

Avacta have gone so quiet since appointment of new CFO.

We all don’t know what’s happening in the back ground.

Brian Hahn has only been in his position for six weeks.

There is a reason why Brian Hahn was head hunted.

His experience with US capital markets and his experience of the advisory committee of the Securities and Exchange Commission on Small and Emerging Companies will help Avacta navigate to a NASDAQ listing and eventual T/O.

From RNS

Mr Hahn currently serves as co-chairman of the BIO Finance and Tax Committee, as a co-chairman of the Steering Committee of the Washington, DC chapter of the Association for Bio Financial Officers (ABFO) and has also served on the Securities and Exchange Commissions’ Advisory Committee on Small and Emerging Companies.

Brian Hahn

“I look forward to leveraging my experience to help accelerate Avacta’s growth and strengthen its position in both the U.K. and U.S. capital markets.”

Do you really think he would join Avacta for it to go bust a few months later…..

Patience is needed he has done DD on Avacta’s finances before taking the role.

The is a reason for the silence if I had seen any negative trial data, I would have reduced my holding considerably,but the data gets stronger every update.

One day Rodney that golden RNS will land and I can leave the AIM market and this dire LSE board for ever….

GLA

Keep hold of those golden tickets…..

Are they quiet because they can’t say anything ie: T/O talks ?????

GLA

The amended Practice Statement 31 sets out a new practice that has been adopted by

the Executive in respect of private sale processes. Where a company is genuinely

initiating a private sale process, the Executive considers that the requirements in Rules

2.4(a) and (b) to identify in a subsequent announcement any potential offeror with

which the company is in talks, or from which an approach has been received, may

operate in an inappropriate manner. Instead, it may be acceptable for the company to

be required to identify a potential offeror only if it has been specifically identified in

any relevant rumour or speculation, and the amended Practice Statement 31 sets out

how the Executive will normally grant dispensations from Rule 2.4(a) and (b) to that

effect.

https://www.thetakeoverpanel.org.uk/wp-content/uploads/2024/04/Panel-Statement-2024_12.pdf

New guidance published last year on UK Public M&A – Recent Guidance and Best Practice Note from the UK Takeover Panel Executive

https://www.gibsondunn.com/uk-public-m-a-recent-guidance-and-best-practice-note-from-the-uk-takeover-panel-executive/

Fudsters starting scare tactics on yearly audit sign off.

Auditors will be given sight of offers on the table for DX, also DX was predicted to be cash generative last quarter so all outgoings wages rent etc…being met by DX revenues.

Audit sign off will be a formality and Avacta won’t require fund raise this year.

Page 62 2003 accounts

Judgements:

During the year, the Committee considered the following key judgements made in preparation of the financial statements:

Going concern - The judgement of whether or not the accounts should be prepared on a going concern basis, as detailed in the Financial Review. The Committee has reviewed detailed cash flow forecasts that extend to at least twelve months from the date of approval of the financial statements. The forecasts take into account the Directors' views of current and future economic conditions that are expected to prevail over the period. These forecasts include assumptions regarding the status of therapeutic development collaborations, the AVA6000 clinical trials, product development projects together with the Launch and Coris sales pipelines, future revenues and costs, together with various scenarios which reflect growth plans, opportunities, risks and mitigating actions. The forecasts also include assumptions regarding the timing and quantum of investment in the therapeutic development programmes

investment in the therapeutic development programmes

Whilst there are inherent uncertainties regarding the cash flows associated with the development of both the therapeutic platforms, the Directors are satisfied that the is sufficient discretion and control as to the timing and quantum of cash outflows to ensure that the Company a Group are able to meet their liabilities as they fall due for least twelve months from the date of approval of the final statements and therefore have prepared the financial statements on a going concern basis.

Revenue recognition - Judgements arise from the applicat of IFRS 15 to the Group's revenue streams, as disclosed i Note 1C, as to the timing and nature of revenue recognis in relation to the achievement of milestones

So we are using FDA language:

Clinical meaningfulness:

This term is used by agencies like the FDA and Medicare to determine whether a treatment is approved and covered.

Keep hold of your golden tickets..

GLA

Trying to read RNS on my phone while travelling got mixed up with these bloody adverts on LSE .

They make this site unreadable sometimes…..

The reaction of the SP today shows how naive the AIM market is to this exceptional data from Avacta today.

Smith & Gardiner need to be ashamed of themselves pushing this HCI Loan onto Avacta just because they couldn’t let go of their DX dream. (rant over)

Now from the RNS:

A durable, confirmed PR was observed at 12 weeks in a 79-year-old male patient.

Rapid and complete regression of large skin and visceral metastasis was observed in a 74-year-old male patient.

Rapid and complete regression of large skin and visceral metastasis was observed in a 74-year-old male patient experiencing a MR.

We can all see it but the market can’t……..

The three patients above would have never be allowed to take doxorubicin because they are over 65 years old and due to the toxicity.

But here they are 2 x 74 year olds and a 79 year old all with meaningful tumor shrinkage.

More patients have cancer over 65 years old than under 65 years old, probably twice if not three times more patients over 65 are just left to pass.

Avacta have just announced they have at least doubled the market maybe more for doxorubicin as AVA6000.

One day the market will wake up but we would probably have to wait for FDA approval before the market wakes up….,

Just looked at short tab on Avacta on LSE

It’s showing a number 1 on short

is this news ? Can’t see GSA have reduced ….

Any one know why the 1

We need finance sorting Avacta operating on a cheese string….

Partners in Oncology

At Johnson & Johnson, we are driven by a bold vision to eliminate cancer. We innovate with purpose to lead where medicine is going. But we know that can’t solve the world’s biggest health challenges alone, so our Innovation team is looking for the most promising early innovations and strategic partners that could benefit from our insight and collaboration. We’re excited to be operating at the unique intersection of innovative medicine and technology where some of the biggest advances in healthcare are happening. As a result, our team has deep scientific and commercial expertise that helps us spot and nurture the right opportunities at the right times in oncology and interventional oncology.

https://jnjinnovation.com/partner-spotlight/partners-in-oncology

I hope Simon Bennett is at #JPM25

All major BP are there and he needs step up this year …….

Avacta not presenting ,but will Avacta’s Senior Leadership Team be at #JPM25 #JPM2025.

All the big BP companies are attending and it’s a great networking opportunity.